Caribou Biosciences, Inc. CRBU
1.24
(0.01)
(0.80%)
as of 25 Sep
- Market cap
- $134.0M
- P/E
- 0.0×
Follow CRBU
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (78.27%) | (83.46%) | (78.97%) | (74.28%) |
+8 more TTM periods Free account |
|
| (56.87%) | (63.04%) | (60.62%) | (58.27%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(99.31%) | (122.41%) | (117.02%) | (116.35%) | |
Average Days of Receivables |
48.67 | 54.47 | 64.53 | 81.29 | |
Free Cash Flow per Share |
(1.31) | (1.06) | (1.20) | (1.37) | |
Free Cash Flow |
(132.79) | (101.64) | (112.35) | (127.72) | |
Capital Expenditures |
(37.01) | (0.39) | (1.36) | (2.08) | |
Piotroski F-Score |
2.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(45.52%) | (46.10%) | (42.44%) | (43.46%) | |
Accounts Receivable Turnover |
5.96 | 6.22 | 5.49 | 4.72 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
854.70% | 843.69% | 980.72% | 1,248.93% | |
Selling, General and Administrative Expense of Revenue |
336.20% | 323.53% | 339.76% | 428.43% | |
Share Based Compensation of Revenue |
104.66% | 99.57% | 113.63% | 149.04% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.76 | 0.75 | 0.80 | |
Depreciation/Fixed assets |
0.34 | 0.35 | 0.37 | 0.28 | |
Capex/Depreciation |
(19.70) | (0.18) | (0.54) | (0.97) | |
Revenue per Share |
0.10 | 0.12 | 0.12 | 0.10 | |
Operating CF per Share |
(0.95) | (1.06) | (1.19) | (1.35) | |
Capex per Share |
(0.37) | 0.00 | (0.01) | (0.02) | |
Capex to Sales |
3.69 | 0.03 | 0.12 | 0.22 | |
Net Profit Margin |
(1,030.42%) | (1,189.14%) | (1,327.40%) | (1,690.45%) |
Columns are period end dates